Daiichi Sankyo Co. Ltd.'s Fiscal Year is From April To March - All Figures are in JPY, Billions.
The item "Research-and-Development" stands at 441.24 Billion Japanese Yens for the trailing twelve months (TTM) period ending 06/30/2025, the highest value at least since 12/31/2011, the period currently displayed.
Daiichi Sankyo Co. Ltd.'s first quarter result of 105.95 Billion JPY for the item "Research and Development" represents a decrease of -20.55 percent compared to it's fourth quarter result of the company's last fiscal year.
Also, Daiichi Sankyo Co. Ltd.'s first quarter result of 105.95 Billion JPY for the item "Research and Development" represents an increase of 5.20 percent compared to it's first quarter result of last year.
Looking again at the trailing twelve months series (TTM), Daiichi Sankyo Co. Ltd.'s first quarter result of 441.24 Billion JPY for the item "Research and Development" represents an increase of 1.20 percent compared to it's fourth quarter result of the company's last fiscal year.
Regarding the One-Year-Change of the series, the current value constitutes an increase of 13.50 percent compared to the value the year prior.
The 1 year change in percent is 13.50.
The 3 year change in percent is 56.97.
The 5 year change in percent is 115.09.
The 10 year change in percent is 123.20.
| Logo | Name | Market Cap (USD) |
|---|---|---|
![]() | Eli Lilly and Company - Research and Development | 905,699,262,464.00 |
![]() | Johnson & Johnson - Research and Development | 486,508,953,600.00 |
![]() | AbbVie Inc - Research and Development | 399,570,305,024.00 |
![]() | Roche Holding AG - Research and Development | 317,433,206,677.55 |
![]() | AstraZeneca PLC - Research and Development | 280,205,508,085.11 |